已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer.

医学 肺癌 肿瘤科 内科学 前瞻性队列研究 靶向治疗 癌症 生殖系 种系突变 突变 基因 生物化学 化学
作者
Justin Jee,Emily S. Lebow,Yonina R. Murciano‐Goroff,Gowtham Jayakumaran,Ronglai Shen,A. Rose Brannon,Ryma Benayed,Azadeh Namakydoust,Michael Offin,Paul K. Paik,Helena A. Yu,Mark T.A. Donoghue,Ahmet Zehir,Alexander Drilon,David B. Solit,David R. Jones,Charles M. Rudin,Michael F. Berger,James M. Isbell,Bob T. Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 9009-9009 被引量:7
标识
DOI:10.1200/jco.2021.39.15_suppl.9009
摘要

9009 Background: The effectiveness of circulating tumor DNA (ctDNA) at matching patients to life prolonging therapy has been studied mostly in small cohorts with limited follow up. The prognostic value of ctDNA alterations, particularly those absent on tissue, is also unclear. To address these questions, we studied survival outcomes in a prospective cohort of patients (N = 1002) with non-small cell lung cancer (NSCLC). Methods: Adults with metastatic or recurrent NSCLC were eligible if they had no known driver mutation or a known driver with progression following targeted therapy. Patients were enrolled at Memorial Sloan Kettering Cancer Center (New York, NY) starting October 21, 2016; analysis here is from a snapshot November 1, 2020. All patients had ctDNA sequenced via the Resolution ctDx Lung platform. To reduce inclusion of incidental germline mutations, we excluded non-functionally significant mutations with an allele frequency 35-65% that were present in gnomAD. Patients could also receive, at their provider’s discretion, tissue sequencing with MSK-IMPACT, which filters germline and clonal hematopoietic (CH) mutations with matched white blood cell sequencing. We performed survival analyses using Cox proportional hazards models from time of diagnosis of advanced disease to death, left truncating at time of study entry. Results: Of 1002 patients, 348 (35%) were treated with targeted therapy; in 181 of these (52%) the targetable alteration was detected in ctDNA. Patients treated with targeted therapy had prolonged survival whether matched by tissue-based methods (HR 0.39, 95%CI 0.30-0.51) or ctDNA (HR 0.47, 95%CI 0.37-0.61). These benefits persisted across multiple subgroups. ctDNA alterations themselves were associated with worse survival (HR 2.2, 95%CI 1.8-2.8), in a manner that scaled with allele fraction and burden. Of 401 patients with time-matched tissue sampling, 62 (15%) had ctDNA alterations that were absent on IMPACT (“unique” ctDNA alterations). Three such patients had unique ctDNA EGFR T790M mutations leading to changes in therapy. However, unique ctDNA alterations were generally associated with worse survival than no ctDNA alterations (HR 2.5, 95%CI 1.7-3.7) and even tissue-matched ctDNA alterations (HR 1.7, 95%CI 1.1-2.4). Of 98 unique ctDNA mutations, 48 (49%) were detectable in tissue at subthreshold levels, 12 (12%) were filtered by IMPACT as CH or germline, and 38 mutations (39%) were absent even at subthreshold levels. ctDNA alteration burden correlated with radiographic disease extent. In multivariate models with radiographic disease extent and other clinical variables, ctDNA alterations were the strongest independent predictor of worse survival. Conclusions: Our results show that ctDNA may match patients to life-prolonging targeted therapy and have prognostic importance. ctDNA may provide data about a patient’s cancer missed by spatially restricted tissue sequencing. Clinical trial information: NCT01775072.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苏幕完成签到,获得积分10
1秒前
锦七完成签到,获得积分10
4秒前
5秒前
al完成签到 ,获得积分10
7秒前
阿梅梅梅完成签到,获得积分10
7秒前
tanglu完成签到,获得积分10
9秒前
小zz完成签到 ,获得积分10
9秒前
哭泣的丝完成签到 ,获得积分10
9秒前
11秒前
孙一一完成签到 ,获得积分10
11秒前
一直向前发布了新的文献求助10
15秒前
万能图书馆应助小何采纳,获得10
16秒前
安详向日葵完成签到 ,获得积分10
17秒前
18秒前
Eins完成签到 ,获得积分10
19秒前
20秒前
confident完成签到 ,获得积分10
22秒前
22秒前
24秒前
科研通AI2S应助momo采纳,获得10
25秒前
可爱邓邓完成签到 ,获得积分10
26秒前
zm_qian发布了新的文献求助10
26秒前
典雅雁梅完成签到 ,获得积分10
26秒前
Bressanone完成签到,获得积分10
28秒前
30秒前
小飞完成签到 ,获得积分10
30秒前
31秒前
补喵发布了新的文献求助10
31秒前
Tsin778完成签到 ,获得积分10
33秒前
Lionnn发布了新的文献求助10
35秒前
棠棠完成签到 ,获得积分10
37秒前
38秒前
40秒前
可爱的函函应助Philip采纳,获得10
40秒前
zxy完成签到 ,获得积分10
44秒前
补喵完成签到,获得积分10
45秒前
50秒前
nulinuli完成签到 ,获得积分10
50秒前
50秒前
Leon Lai完成签到,获得积分10
51秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256000
捐赠科研通 3270880
什么是DOI,文献DOI怎么找? 1805070
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216